The biology behind why cannabis-based medicines work for MS spasticity | Research

The takeaway

The endocannabinoid system plays a fundamental role in controlling neurotransmission disrupted in MS, providing the biological rationale for why cannabis-based medicines reduce spasticity.

Read this if you want to understand the science behind why cannabis helps MS symptoms.

Endocannabinoid system directly controls neurotransmission disrupted in MS

What the researchers found

This review connected the biology of MS to the biology of the endocannabinoid system, explaining why cannabis-based medicines work for spasticity at a fundamental level. MS damages myelin and impairs neurotransmission. Cannabinoid receptors and endocannabinoids naturally regulate neurotransmission, making them logical therapeutic targets.

The review traced the path from MS patients self-medicating with street cannabis, through preclinical validation in animal models of MS, to the approval of cannabis-based medicines. The endocannabinoid system was positioned not just as a symptomatic treatment target but as potentially relevant to the accumulation of progressive disability in MS.

Why it matters

Understanding why cannabis-based medicines work, not just that they work, helps guide further drug development and identifies which patients might benefit most.

The numbers in context

Cannabis-based medicines approved for pain and spasticity in MS at time of publication.

How the study worked

Review article connecting MS disease biology to endocannabinoid system biology. Integrated preclinical animal model data with clinical approval evidence for cannabis-based medicines.

What this study cannot tell us

Review by authors in the field. The disease modification argument was largely preclinical. The biological rationale, while logical, does not guarantee clinical efficacy for all applications.

How to read the evidence

Review integrating basic science and clinical evidence. Provides a strong mechanistic framework but the disease modification argument was speculative.

When this study was published

Published in 2012. Cannabis-based medicines for MS are now widely approved and prescribed.

The bigger picture

The biological rationale reviewed here extended beyond symptom control. If the endocannabinoid system can influence disease progression through neuroprotection and regulation of neurotransmission, cannabinoid medicines could potentially address both symptoms and disease course.

Questions still open

Can endocannabinoid system biology predict which MS patients respond best to cannabinoid treatment? Do endocannabinoid levels change during MS progression? Could targeted cannabinoid therapies slow disability accumulation?

Common questions

Why does cannabis help with MS spasticity?

MS damages the myelin that insulates nerve fibers, disrupting how signals travel in the brain and spinal cord. The endocannabinoid system naturally regulates these nerve signals. Cannabis-based medicines activate this system to help restore more normal signal transmission, reducing spasticity.

Could cannabis slow MS progression?

Preclinical evidence suggested possible anti-inflammatory and neuroprotective effects that could slow progression. However, this has not been convincingly demonstrated in human clinical trials.

Read the original research

The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis.

Multiple sclerosis and related disorders, 1(2), 64-75

View on PubMed ↗Publisher’s paper ↗

Citation

Baker, David; Pryce, Gareth; Jackson, Samuel J; Bolton, Chris; Giovannoni, Gavin. (2012). The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis.. Multiple sclerosis and related disorders, 1(2), 64-75. https://doi.org/10.1016/j.msard.2011.11.001